Galena price target raised to $9 from $6 at Maxim Maxim raised its price target for Galena shares to $9 citing increased confidence in the development pipeline after the company said it started enrollment of a phase II trial for its second anti-cancer agent GALE-301. The firm reiterates a Buy rating on the stock.
Galena receives notice of allowance of U.S. patent for NeuVax Galena Biopharma announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax. NeuVax is a peptide immunotherapy currently being evaluated for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.